FDA Initiates Safety Study on Mifepristone Amid Legal Challenges
The Food and Drug Administration (FDA) has commenced a safety study of the abortion pill Mifepristone, a move that could lead to restrictions on its distribution by the Trump administration. This development follows a Supreme Court decision in May that allowed the continued prescription of the pill via telemedicine and mail, despite ongoing legal challenges from Louisiana. The study, supported by the White House, is expected to last six months and aims to withstand legal scrutiny. Mifepristone is a key component in medical abortions, which account for a significant portion of abortion procedures in the U.S. 
